Global Inflammatory Bowel Disease Market 2015-2019

炎症性腸疾患(IBD)治療薬の世界市場:クローン病、潰瘍性大腸炎

◆タイトル:Global Inflammatory Bowel Disease Market 2015-2019
◆商品コード:IRTNTR5692
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年4月15日
◆ページ数:146
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、炎症性腸疾患(IBD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、パイプライン動向、炎症性腸疾患(IBD)治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Inflammatory Bowel Disease
Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn’s disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn’s disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn’s disease causes inflammation of the lining of the GI tract. The inflammation in Crohn’s disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management.The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors.

TechNavio’s analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn’s Disease and Ulcerative Colitis.

On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments.
• 5-ASA
• Antibiotics
• Immunomodulators

On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Biologics
• Small Molecules

On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Oral
• Parenteral

On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Solid
• Liquid

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Inflammatory Bowel Disease market. The vendor landscape includes an analysis of the major vendors, along with the competitive performances of their portfolios. In addition, the report discusses the major drivers, challenges and trends influencing the market. In addition, late-stage pipeline molecules developed for the treatment of inflammatory bowel disease are discussed.TechNavio’s report, Global Inflammatory Bowel Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the landscape of the Global Inflammatory Bowel Disease market and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Abbvie
• Biogen Idec
• Janssen Pharmaceuticals
• Merck & Company
• Shire
• UCB

[Other Prominent Vendors]
• Amgen
• Akebia Therapeutics
• Boehringer Ingelheim
• Celltrion
• ChemoCentryx
• Ferring Pharmaceuticals
• Galapagos
• Genentech
• Merck
• Mitsubishi Tanabe
• Novartis
• Novo Nordisk
• Pfizer
• Salix Pharmaceuticals

[Market Driver]
• Increase in Instances of Inflammatory Bowel Disease
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Drugs
• For a full, detailed list, view our report

[Market Trend]
• Dominance of Market by Biologics
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market overview
03.2 Product offerings

04.Market Research Methodology
04.1 Market research process
04.2 Research methodology

05.Introduction

06.Disease Overview: Crohn’s Disease
06.1 Understanding the disease
06.2 Etiology
06.2.1 Autoimmune reaction
06.2.2 Genes
06.2.3 Environment
06.3 Stages of Crohn’s disease
06.4 Epidemiology
06.4.1 Worldwide prevalence of Crohn’s disease
06.4.2 US
06.4.3 UK
06.5 Symptoms
06.5.1 Diarrhea
06.5.2 Fever and fatigue
06.5.3 Abdominal pain and cramping
06.5.4 Perianal disease and blood in stool
06.5.5 Reduced appetite and weight loss
06.6 Diagnosis and testing
06.6.1 Early tests and exams
06.6.2 Endoscopy and biopsy
06.6.3 Chromoendoscopy
06.6.4 Small intestinal imaging
06.7 Treatment
06.7.1 Medication
06.7.2 Diet and nutrition
06.7.3 Surgery

07.Disease Overview: Ulcerative Colitis
07.1 Understanding the disease
07.2 Etiology
07.2.1 Autoimmune reaction
07.2.2 Genetics
07.2.3 Environmental factors
07.3 Prognosis
07.4 Epidemiology
07.4.1 Global
07.4.2 UK
07.4.3 US
07.5 Symptoms
07.6 Diagnosis and testing
07.7 Treatment
07.7.1 Medical treatment options
07.7.2 Surgical procedures

08.Pipeline Portfolio
08.1 Crohn’s disease pipeline landscape
08.1.1 Some emerging therapeutic options
08.2 Ulcerative colitis pipeline landscape

09.Market Landscape
09.1 Global inflammatory bowel disease market
09.2 Market size and forecast
09.3 Inflammatory bowel disease market in US
09.3.1 Market size and forecast
09.4 Inflammatory bowel disease market in EU
09.4.1 Market size and forecast
09.5 Inflammatory bowel disease market in Japan
09.5.1 Market size and forecast
09.6 Five forces analysis

10.Market Segmentation by Type of Disease
10.1 Crohn’s disease
10.2 Ulcerative colitis

11.Global Crohn’s Disease Market
11.1 Market size and forecast
11.2 Crohn’s disease market in US
11.2.1 Market size and forecast
11.3 Crohn’s disease market in Japan
11.3.1 Market size and forecast

12.Global Ulcerative Colitis Market
12.1 Market size and forecast

13.Market Segmentation by Drug Class

14.Market Segmentation by Type of Molecule
14.1 Biologics
14.2 Small molecules

15.Market Segmentation by Dosage Form
15.1 Solid
15.2 Liquid

16.Market Segmentation by Route of Administration
16.1 Oral
16.2 Parenteral

17.Geographical Segmentation
17.1 Segmentation of global inflammatory market by geography
17.2 Segmentation of global Crohn’s disease and ulcerative colitis markets by geography
17.3 Segmentation of global Crohn’s disease market by geography
17.4 Segmentation of global ulcerative colitis market by geography

18.Key Leading Countries
18.1 Key leading countries 2014
18.2 Key leading countries 2019
18.3 US
18.4 Japan

19.Buying Criteria

20.Market Growth Drivers

21.Drivers and their Impact

22.Market Challenges

23.Impact of Drivers and Challenges

24.Market Trends

25.Trends and their Impact

26.Vendor Landscape
26.1 Competitive scenario
26.1.1 Key news
26.1.2 Mergers and acquisitions
26.2 Market share analysis 2014
26.2.1 Competitive assessment of top drugs for inflammatory bowel disease
26.2.2 AbbVie
26.2.3 Janssen Pharmaceuticals
26.2.4 Merck
26.2.5 Biogen Idec
26.2.6 UCB
26.2.7 Shire
26.3 Other and future prominent vendors

27.Key Vendor Analysis
27.1 AbbVie
27.1.1 Key facts
27.1.2 Business overview
27.1.3 Product segmentation by revenue 2013
27.1.4 Product segmentation by revenue 2012 and 2013
27.1.5 Sales by geography
27.1.6 Business strategy
27.1.7 Key developments
27.1.8 SWOT analysis
27.2 Biogen Idec
27.2.1 Key facts
27.2.2 Business overview
27.2.3 Business segmentation by revenue 2013
27.2.4 Geographical segmentation by revenue 2013
27.2.5 Business strategy
27.2.6 Key developments
27.2.7 SWOT analysis
27.3 Janssen Pharmaceuticals
27.3.1 Key facts
27.3.2 Business overview
27.3.3 Recent developments
27.3.4 SWOT analysis
27.4 Merck
27.4.1 Key facts
27.4.2 Business overview
27.4.3 Business segmentation by revenue 2013
27.4.4 Business segmentation by revenue 2012 and 2013
27.4.5 Sales by geography
27.4.6 Business strategy
27.4.7 Key developments
27.4.8 SWOT analysis
27.5 Shire
27.5.1 Key facts
27.5.2 Business overview
27.5.3 Geographical segmentation by revenue 2013
27.5.4 Business strategy
27.5.5 Recent developments
27.5.6 SWOT analysis
27.6 UCB
27.6.1 Key facts
27.6.2 Business overview
27.6.3 Product segmentation by revenue 2013
27.6.4 Product segmentation by revenue 2012 and 2013
27.6.5 Geographical segmentation by revenue 2013
27.6.6 Business strategy
27.6.7 Recent developments
27.6.8 SWOT analysis

28.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market research methodology
Exhibit 2: Challenges and drivers of global inflammatory bowel disease market
Exhibit 3: Overview of Crohn’s disease
Exhibit 4: Classification of Crohn’s disease
Exhibit 5: Expected number of global Crohn’s disease cases 2015-2022
Exhibit 6: Global variation in incidence rates for Crohn’s disease in 2012 (in %)
Exhibit 7: Prevalence of Crohn’s disease in US
Exhibit 8: Incidence of Crohn’s disease in US
Exhibit 9: Symptoms of Crohn’s disease
Exhibit 10: Crohn’s disease: diagnosis and testing
Exhibit 11: Crohn’s disease: treatment
Exhibit 12: Treatment landscape for Crohn’s disease
Exhibit 13: Crohn’s disease: treatment pathway
Exhibit 14: Ulcerative colitis: Symptoms
Exhibit 15: Diagnostic approach for ulcerative colitis
Exhibit 16: Treatment options for ulcerative colitis
Exhibit 17: Surgical procedures to treat ulcerative colitis
Exhibit 18: Crohn’s disease: pipeline portfolio
Exhibit 19: Crohn’s disease clinical trial by phase
Exhibit 20: Crohn’s disease clinical trial by status
Exhibit 21: Ulcerative colitis: pipeline portfolio
Exhibit 22: Snapshot of global inflammatory bowel disease market 2014
Exhibit 23: Global inflammatory bowel disease market 2014-2019 ($ million)
Exhibit 24: Inflammatory bowel disease market in US 2014-2019 ($ million)
Exhibit 25: Inflammatory bowel disease market in EU 2014-2019 ($ million)
Exhibit 26: Inflammatory bowel disease market in Japan 2014-2019 ($ million)
Exhibit 27: Segmentation of global inflammatory bowel disease market by type of disease
Exhibit 28: Segmentation of global inflammatory bowel disease market by type of disease 2014
Exhibit 29: Segmentation of global inflammatory bowel disease market by type of disease 2019
Exhibit 30: Revenue of global inflammatory bowel disease market 2014-2019 ($ million)
Exhibit 31: Snapshot of global Crohn’s disease market 2014
Exhibit 32: Global Crohn’s disease market 2014-2019 ($ million)
Exhibit 33: Crohn’s disease market in US 2014-2019 ($ million)
Exhibit 34: Crohn’s disease market in Japan 2014-2019 ($ million)
Exhibit 35: Snapshot of global ulcerative colitis market
Exhibit 36: Global ulcerative colitis market 2014-2019 ($ million)
Exhibit 37: Segmentation of global inflammatory bowel disease market by drug class
Exhibit 38: Benefits and risks of 5-ASA
Exhibit 39: Segmentation of global inflammatory bowel disease market by drug class 2014
Exhibit 40: Segmentation of global inflammatory bowel disease market by type of molecule
Exhibit 41: Segmentation of global inflammatory bowel disease market by type of molecule 2014
Exhibit 42: Segmentation of global inflammatory bowel disease market by dosage form
Exhibit 43: Segmentation of global inflammatory bowel disease market by dosage form 2014
Exhibit 44: Segmentation of global inflammatory bowel disease market by route of administration
Exhibit 45: Segmentation of global inflammatory bowel disease market by route of administration 2014
Exhibit 46: Segmentation of global inflammatory bowel disease market by geography 2014
Exhibit 47: Segmentation of global inflammatory bowel disease market by geography 2019
Exhibit 48: Segmentation of global Crohn’s disease market by geography 2014
Exhibit 49: Segmentation of global ulcerative colitis market by geography 2014
Exhibit 50: Major drivers of global inflammatory bowel disease market
Exhibit 51: Major challenges in global inflammatory bowel disease market
Exhibit 52: Major trends in global inflammatory bowel disease market
Exhibit 53: Ranking of vendors 2014
Exhibit 54: YoY revenue of top drugs for inflammatory bowel disease 2010-2014 ($ million)
Exhibit 55: Revenue share of top drugs for inflammatory bowel disease 2010-2014
Exhibit 56: AbbVie: product portfolio
Exhibit 57: YoY global revenue of Humira 2009-2014 ($ million)
Exhibit 58: YoY revenue of Humira in US 2009-2014 ($ million)
Exhibit 59: YoY international revenue of Humira (except US) 2009-2014 ($ million)
Exhibit 60: Revenue comparison of Humira 2009-2014 ($ million)
Exhibit 61: Janssen: product portfolio
Exhibit 62: YoY global revenue of Remicade 2009-2014 ($ million)
Exhibit 63: YoY global revenue of Simponi 2010-2014 ($ million)
Exhibit 64: Merck: product portfolio
Exhibit 65: YoY global revenue of Remicade 2009-2014 ($ million)
Exhibit 66: YoY global revenue of Simponi 2010-2014 ($ million)
Exhibit 67: Biogen Idec: product portfolio
Exhibit 68: YoY global revenue of Tysabri 2009-2014 ($ million)
Exhibit 69: YoY revenue of Tysabri in US 2009-2014 ($ million)
Exhibit 70: YoY revenue of Tysabri in ROW 2009-2014 ($ million)
Exhibit 71: Global revenue of Tysabri 2009-2014 ($ million)
Exhibit 72: UCB: product portfolio
Exhibit 73: YoY global revenue of Cimzia 2010-2014 ($ million)
Exhibit 74: Shire: product portfolio
Exhibit 75: YoY global revenue of Lialda 2010-2014 ($ million)
Exhibit 76: AbbVie: product segmentation by revenue 2013
Exhibit 77: AbbVie: product segmentation by revenue 2012 and 2013 ($ million)
Exhibit 78: AbbVie: sales by geography 2013
Exhibit 79: Biogen Idec: business segmentation by revenue 2013
Exhibit 80: Biogen Idec: geographical segmentation by revenue 2013
Exhibit 81: Merck: business segmentation by revenue 2013
Exhibit 82: Merck: business segmentation by revenue 2012 and 2013 ($ billion)
Exhibit 83: Merck: sales by geography 2013
Exhibit 84: Shire: geographical segmentation by revenue 2013
Exhibit 85: UCB: product segmentation by revenue 2013
Exhibit 86: UCB: product segmentation by revenue 2012 and 2013 ($ million)
Exhibit 87: UCB: geographical segmentation by revenue 2013



【掲載企業】

AbbVie Inc., Biogen Idec Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Shire plc and UCB SA., Amgen, Akebia Therapeutics, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Galapagos, Genentech, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer and Salix Pharmaceuticals

【資料のキーワード】

炎症性腸疾患、炎症性腸疾患治療薬、クローン病治療薬、潰瘍性大腸炎治療薬、症状、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[炎症性腸疾患(IBD)治療薬の世界市場:クローン病、潰瘍性大腸炎] (Global Inflammatory Bowel Disease Market 2015-2019 / IRTNTR5692)販売に関する免責事項
[炎症性腸疾患(IBD)治療薬の世界市場:クローン病、潰瘍性大腸炎] (Global Inflammatory Bowel Disease Market 2015-2019 / IRTNTR5692)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆